Trial Profile
Safety and efficacy of palbociclib in patients with advanced stage endocrine sensitive/HER2 negative breast cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Jun 2018
Price :
$35
*
At a glance
- Drugs Palbociclib (Primary) ; Anastrozole; Exemestane; Fulvestrant; Letrozole; Tamoxifen
- Indications HER2 negative breast cancer
- Focus Adverse reactions; Therapeutic Use
- 12 Jun 2018 New trial record
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology